Ivabradine: Recent and potential applications in clinical practice

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 3, 2011, Pages 443-450

  Riccioni, Graziano ^a  

^a SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

Author keywords

cardiovascular disease; chronic stable angina; heart rate; If current; ivabradine; myocardial infarction; postural tachycardia syndrome

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; IVABRADINE; METOPROLOL; PLACEBO;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ARTICLE; BRADYCARDIA; CAROTID ATHEROSCLEROSIS; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; HEART LEFT VENTRICLE FAILURE; HEART RATE; HEART TRANSPLANTATION; HUMAN; INAPPROPRIATE SINUS TACHYCARDIA; MORBIDITY; MORTALITY; NONHUMAN; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINUS TACHYCARDIA; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; SYSTOLIC HEART FAILURE; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER;

ANGINA PECTORIS; ANIMALS; BENZAZEPINES; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FEMALE; HEART RATE; HUMANS; MALE; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79251473739     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.548321     Document Type: Article

References (69)

1. Kannel WB, Kannel C, Paffenbarger RS, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987;113:1489-94
2. Perret-Guillaume C, Joly L, Benetos A. Heart rate as a risk factor for cardiovascular disease. Prog Cardiovasc Dis 2009;52:6-10
3. Hjalmarson A, Gilpin EA, Kjekshus G, et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990;1:547-53
4. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J 1999;1:64-9
5. Tardif JC Heart rate as a treatable cardiovascular risk factor. Br Med Bull 2009;90:71-84
6. Verrier RL, Tan A. Heart rate, autonomic markers, and cardiac mortality. Heart Rhythm 2009;6:68-75
7. Shaper AG, Wannamethee G, Macfarlane PG, Walker M. Heart rate, ischemic heart disease, and sudden cardiac death in middle-aged British men. Br Heart J 1993;70:49-55
8. Fox K, Borer JS, Camm AJ, et al. Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007;50:823-30
9. Bortone AS, Hess OM, Gaglione A, et al. Effect of propranolol on coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. Circulation 1990;81:1225-35
10. Tattersfield AE. Respiratory function in the elderly and the effects of beta blockade. Cardiovasc Drugs Ther 1991;4:1229-32
11. Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in a double-blind crossover study in hypertensive patients. Blood Press 1992;1:92-101
12. Fernandez SF, Tandar A, Boden WE. Emerging medical treatment for angina pectoris. Expert Opin Emerg Drugs 2010;15:283-98
13. Rosano GM, Vitale C, Volterrani M. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction. Adv Ther 2010;27:202-10
14. Riccioni G. Ivabradine: from molecular basis to clinical effectiveness. Adv Ther 2010;27:160-7
15. Baruscotti M, Barbuti A, Bucchi A. The cardiac pacemaker current. J Mol Cell Cardiol 2010;48:55-64
16. DiFrancesco D, Borer JS. The funny current: cellular basis for the control of heart rate. Drugs 2007;67:15-24
17. DiFrancesco D. The role of the funny current in pacemaker activity. Circ Res 2010;106:434-46
18. Summary of Product Characteristics. ProcoralanTM (ivabradine hydrochloride). Servier Laboratories Ltd. October 2005. Available from: http://emc.medicines.org.uk; European Public Assessment Report (EPAR): Scientific discussion for Procoralan.
19. EMEA, London. Available from: http://www.emea.eu.int
20. Borer JS, Tardif JC Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus. Am J Cardiol 2010;105:29-35
21. Manz M, Reuter M, Lauck G, et al. A single dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003;100:149-55
22. De Ferrari GM, Mazzuero A, Agnesina L, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail 2008;10:550-5
23. Riccioni G. Focus on ivabradine: a new heart rate-controlling drug. Expert Rev Cardiovasc Ther 2009;7:107-13
24. Liang M, Puri A, Devlin G. Heart rate and cardiovascular disease: an alternative to beta blockers. Cardiol Res Pract 2009;2009:179350
25. Fox K, Ford I, Steg PG, et al. BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. Lancet 2008;372:807-16
26. Savelieva I, Camm AJ. Novel If current inhibitor ivabradine: safety considerations. Adv Cardiol 2006;43:79-96
27. Murat SN, Orcan S, Akdemir R, et al. Arrhythmic effects of ivabradine in patients with coronary artery disease. Clin Invest Med 2009;32:322-6
28. Tardif JC Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases. Drugs Today 2008;44:171-81
29. Tardif JC, Ponikowski T, Kahan T.; for the ASSOCIATE Study investigators. Efficacy of If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4 month, randomized, placebo-controlled trial. Eur Heart J 2009;26:2529-36
30. Tardif JC, Ford I, Tendera M, et al.; INITIATIVE Investigators. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529-36
31. De Silva R, Fox KM. Angina: ivabradine for treatment of stable angina pectoris. Nat Rev Cardiol 2009;6:329-30
32. Ripa C, Germano G, Caparra A, et al. Ivabradine use in refractory unstable angina: a case report. Int J Immunopathol Pharmacol 2009;22:849-52
33. Koster R, Kaehler J, Meinertz T.; REDUCTION Study Group. Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study. Am Heart J 2009;158:51-7
34. Tendera M, Borer JS, Tardif JC. Efficacy of I(f) inhibition with ivabradine in different subpopulations with stable angina pectoris. Cardiology 2009;114:116-25
35. Fox K, Ford I, Steg PG, et al.; BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008;372:817-21
36. Fox K, Ford I, Steg PG, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009;30:2337-45
37. Yusuf S, Camm AJ. Sinus tachyarrhythmias and the specific bradycardic agents: a marriage made in heaven? J Cardiovasc Pharmacol Ther 2003;8:89-105
38. Calo L, Rebecchi M, Sette A, et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm 2010;7:1318-23
39. Sette A, Martino A, Lioy E, Calo L. Efficacy of ivabradine in a case of inappropriate sinus tachycardia and ventricular dysfunction. J Cardiovasc Electrophysiol 2010;21:815-17
40. De Sisti A, Tonet J, Benkaci A, Frank R. A case of inappropriate sinus tachycardia after atrio-ventricular nodal reentrant tachycardia cryoablation successfully treated by ivabradine. Europace 2010;12:1029-31
41. Schulze V, Steiner S, Hennersdorf M, Strauer BE. Ivabradine as an alternative therapeutic trial in the therapy of inappropriate sinus tachycardia: a case report. Cardiology 2008;110:206-8
42. Capulzini L, SarkozyA, Semeraro O, et al. Ivabradine to treat inappropriate sinus tachycardia after the fast pathway ablation in a patient with severe pectus excavatum. Pacing Clin Electrophysiol 2010;33:32-5
43. Winum PF, Cayla G, Rubini M, et al. A case of cardiomyopathy induced by inappropriate sinus tachycardia and cured by ivabradine. Pacing Clin Electrophysiol 2009;32:942-4
44. Kaplinsky E, Comes FP, Urondo LS, Ayma FP. Efficacy of ivabradine in four patients with inappropriate sinus tachycardia: a three month-long experience based on electrocardiographic, Holter monitoring, exercise tolerance and quality of life assessments. Cardiol J 2010;17:166-71
45. Kumar S, Vohra J. Ivabradine: appropriate treatment for inappropriate sinus tachycardia. Heart Rhythm 2010;7:1324-5
46. Ewan V, Norton M, Newton JL. Symptom improvement in postural orthostatic tachycardia syndrome with the sinus node blocker ivabradine. Europace 2007;9:1202
47. Doesch AO, Celik S, Ehlermann P, et al. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine. Transplantation 2007;84:988-96
48. Zhang R, Haverich A, Struber M, et al. Effects of ivabradine on allograft function and exercise performance in heart transplant recipients with permanent sinus tachycardia. Clin Res Cardiol 2008;97:811-19
49. Doesch AO, Ammon K, Konstandin M, et al. Heart rate reduction for 12 months with ivabradine reduces left ventricular mass in cardiac allograft recipients. Transplantation 2009;88:835-41
50. Zwicker C, Becker M, Lepper W, et al. Cardiogenic shock due to tachycardiomyopathy after heart transplantation: successful treatment with ivabradine. Cardiology 2010;116:174-7
51. Fasullo S, Cannizzaro S, Maringhini G, et al. Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings. J Card Fail 2009;15:856-63
52. Wikstrand J, Berglund G, Hedblad B, Hulthe J. Antiatherosclerotic effects of beta-blockers. Am J Cardiol 2003;91:25-9
53. Hedblad B, Wikstrand J, Janzon L, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001;103:1721-6
54. Wiklund O, Hulthe J, Wikstrand J, et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002;33:572-7
55. Custodis F, Baumhakel M, Schlimmer N, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008;117:2377-87
56. Triggle CR Defying the economists: a decrease in heart rate improves not only cardiac but also endothelial function. Br J Pharmacol 2008;154:727-8
57. Drouin A, Gendron ME, Thorin E, et al. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol 2008;154:749-57
58. Baumhakel M, Custodis F, Schlimmer N, et al. Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice. Atherosclerosis 2010;212:55-62
59. Swedberg K, Komajda M, Bohm M, et al. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail 2010;12:75-81
60. Swedberg K, Komajda M, Bohm M, et al.; on behalf of the SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-85
61. Ferrari R A step further with ivabradine: SIGNIfY (study assessing the morbidity-mortality benefits of the if inhibitor ivabradine in patients with coronary artery disease). Eur Heart J 2009;11(Suppl):D19-27
62. Available from: http://www. controlled-trials.com/ISRCTN66067800/Servier [Last accessed 10 December 2010]
63. Dominguez-Rodriguez A, Fard SS, Abreu-Gonzalez P, et al. Randomised, double-blind, placebo-controlled trial of ivabradine in patients with acute coronary syndrome: effects of the If current inhibitor ivabradine on reduction of inflammation markers in patients with acute coronary syndrome-RIVIERA trial study design and rationale. Cardiovasc Drugs Ther 2009;23:243-7
64. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting HR in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967-74
65. Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1994;90:2645-57
66. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442
67. Heart disease and stroke statistics-2009 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2009;119:21-181
68. Leal J, Luengo-Fernandez R, Gray A, et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006;27:1610-19
69. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J 1999;1:64-9